{
  "docId": "019de075-3c48-75dd-a16f-ddcce5fecf48",
  "docSlug": "20dccf7a034b09514201ed73755b4bbb",
  "documentTitle": "Absci | Investor Presentation Deck | 48 slides",
  "authorId": "absci",
  "authorName": "Absci",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 48,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "other",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide highlights the 'zero-shot' nature of the model, emphasizing the lack of lead optimization and the successful application across four distinct therapeutic targets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-3c48-75dd-a16f-ddcce5fecf48/17",
  "deckHref": "/decks/019de075-3c48-75dd-a16f-ddcce5fecf48",
  "deckJsonHref": "/decks/019de075-3c48-75dd-a16f-ddcce5fecf48.json",
  "deckAnchorHref": "/decks/019de075-3c48-75dd-a16f-ddcce5fecf48#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.42,
        "y": 0.3
      },
      "kind": "image",
      "text": "Molecular structure diagram showing HER2 antigen, heavy chain, light chain, and HCDR3 region.",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ad31a79-54ee-45f6-ae17-f0d964a5f1fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.78,
        "y": 0.7
      },
      "kind": "legend",
      "text": "Legend for molecular structure components (Trastuzumab residues and De Novo HCDR3s).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c15f2fd-644b-4a8d-8a6f-a5d61559f582",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.35,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "list",
      "text": "Zero-Shot: Model has never seen a binder to target or homologs. Binders were identified straight out of the model - no lead optimization was performed. Predicted structures reveal meaningful biological interactions. Demonstrated across four therapeutic targets.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f586231-b899-4d15-8bc1-fae722589c6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "CASE STUDY: DE NOVO DESIGN IN SILICO",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b02daa6-6ee3-4fd9-bbce-8159de968c6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.04,
        "y": 0.1
      },
      "kind": "title",
      "text": "‘Zero-shot’ designs of new antibodies from scratch using generative AI",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d3417a2-448c-4d7a-88ee-e4667b1cf6c0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 48,
      "from": 6,
      "beatId": "7c165ad6-f743-4405-9aff-e111239d7bcd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 6-48 present Absci's AI-powered solution for biologic drug creation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}